Skip to content

Magnesium After Alcohol Withdrawal Treatment

Magnesium After Alcohol Withdrawal Treatment

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00325299
Enrollment
178
Registered
2006-05-12
Start date
Unknown
Completion date
2005-09-30
Last updated
2006-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol-Induced Disorders

Brief summary

The primary purpose is to see if magnesium tablet supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal. The secondary aims are to find out whether supplementation decreases the activity of ASAT and ALAT enzymes, increases muscle strength, decreases blood pressure and decreases depressive symptoms among these patients.

Detailed description

Magnesium (Mg) deficiency is common among alcoholics. Animal studies have shown that magnesium deficiency aggravates the hepatic damage caused by alcohol. One study on chronic alcoholics suggested that magnesium supplementation over six weeks decreases abnormally high activities of three enzymes related to liver function: serum gamma-glutamyltransferase (GGT), aspartate-aminotransferase (ASAT) and alanine-aminotransferase (ALAT), and increases muscle strength \[4\]. These results were, however, significant at the 5% level only when a 1-sided test was applied. It seems that magnesium supplementation may improve liver recovery after a drinking bout, but the evidence is not yet strong enough to warrant clear recommendations for clinical practice. Magnesium deficiency may also be one of the symptoms of depression and may aggravate hypertension. The primary purpose of the present randomized, parallel group, double blind trial is to see if oral magnesium supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal. The secondary aims are to find out whether supplementation decreases the activity of ASAT and ALAT enzymes, increases muscle strength, decreases blood pressure and decreases depressive symptoms among these patients.

Interventions

DRUGMagnesium

Sponsors

Finnish Foundation for Alcohol Studies
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Admission to treatment because of an acute alcohol withdrawal * Elevated serum GGT (men\>80, women \>50) * Age 20-64 years * Fixed address and a telephone to facilitate follow-up

Exclusion criteria

* Mg supplementation within the past two months ten 250 mg tablets or more * History of heart rhythm disturbances * Contraindications against Mg treatment * Abnormally high serum creatinine

Design outcomes

Primary

MeasureTime frame
Serum gamma-glutamyltransferase (GGT) activity

Secondary

MeasureTime frame
Aspartate-aminotransferase (ASAT) activity
Alanine-aminotransferase (ALAT) activity
Depressive symptoms
Blood pressure
Handgrip muscle strength

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 6, 2026